Peptide questions · MariTide
How long does MariTide take to work?
Reviewed Evidence: ModeratePublished by PepVault
MariTide’s onset is days–2 weeks, its peak effect comes at 52 weeks (phase 2 endpoint, no plateau yet), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 1 (Véniant 2024, Nat Metab), phase 2 RCT (Jastreboff 2025, NEJM; NCT05669599), Amgen releases Nov-26-2024, Jun-23-2025 and Feb-3-2026, MARITIME records on ClinicalTrials.gov. Investigational.
MariTide week by week
The library places six of its research notes on MariTide on the days they cover, from day 1 to day 364 and on: 4 on clinical data and 2 on randomized trials.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–56 (weeks 1–8) | A low start, on purpose | Clinical data |
| Days 1–56 (weeks 1–8) | Second step | Clinical data |
| Days 29–112 (weeks 5–16) | The last step before the target dose | Clinical data |
| Days 57–364 (weeks 9–52) | The top monthly dose tested | Randomized trial |
| Days 85–364 (weeks 13–52) | With type 2 diabetes too | Randomized trial |
| From day 365 on | Year two: keeping it off on less | Clinical data |

Model. Individual results vary.
The MariTide timeline’s milestones
The library’s timeline for MariTide marks 4 points from week 1 to week 104, backed by moderate evidence overall.
- Week 1: Commonly reported: nausea in the days after the first dose, more likely at a higher start
- Week 8: Phase 3 finishes its step-up (21, 35, then 70 mg) by about week 8
- Week 52: Phase 2 endpoint: up to about 20% average loss without diabetes, and not yet levelling off
- Week 104: Phase 2 second year: Amgen reported most kept their loss on lower monthly or quarterly doses
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why MariTide takes that long
MariTide’s half-life is about 15 days (360 hours), so one dose is about 96.9% cleared after 75 days.
The library’s frequency for MariTide (“Every 4 weeks (monthly)”) isn’t one fixed interval, so this page computes no build-up for it.
The notes on MariTide follow the trials’ dose steps, 21mg, 35mg, 70mg and 420mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
MariTide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 25 metabolic & GLP-1 compounds, MariTide among them; 17 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| MariTide | Days–2 weeks | 52 weeks (phase 2 endpoint, no plateau yet) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Bofanglutide | Days–2 weeks | 52 weeks (phase 3 endpoint) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
| L-Carnitine (injectable) | Hours (blood levels rise) | 12–24 weeks (muscle carnitine, in the one long trial) |
| Tesofensine | 1–2 weeks (appetite falls) | 12–24 weeks (weight loss in the trial) |
Questions people ask
How long does MariTide take to work?
MariTide’s onset is days–2 weeks, its peak effect comes at 52 weeks (phase 2 endpoint, no plateau yet), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does MariTide reach its peak effect?
By the library’s timeline, MariTide’s peak effect comes at 52 weeks (phase 2 endpoint, no plateau yet), backed by moderate evidence.
How long is MariTide usually run?
The library’s timeline gives MariTide’s typical duration as ongoing; its cycle note says: Used continuously, every 4 weeks, in its trials: 52 weeks in phase 2 and 72 weeks in the phase 3 weight trials.
What does the library say about the first days on MariTide?
Its first note on MariTide, for days 1–56 (weeks 1–8), is “A low start, on purpose”, resting on clinical data.